Faecal M2-pyruvate kinase: A novel, noninvasive marker of ileal pouch inflammation

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 5, 2009, Pages 544-550

  Johnson, Matt W ^a   Maestranzi, Susan ^b   Duffy, Audrey M ^b   Dewar, David H ^c   Ciclitira, Paul J ^c   Sherwood, Roy A ^b   Nicholls, John R ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Ileal pouch anal anastomosis; Medical management; Noninvasive inflammatory marker; Pouchitis; Pyruvate kinase; Restorative proctocolectomy; Surveillance

Indexed keywords

CALGRANULIN; PYRUVATE KINASE;

ADENOMATOUS POLYP; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCTOCOLECTOMY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADENOMATOUS POLYPOSIS COLI; ADULT; BIOLOGICAL MARKERS; CLINICAL ENZYME TESTS; COLITIS, ULCERATIVE; COLONOSCOPY; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; POUCHITIS; PYRUVATE KINASE; SEVERITY OF ILLNESS INDEX;

EID: 67651180580     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283040cb3     Document Type: Article

References (40)

1. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986; 1:167-174.
2. Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987; 40:601-607. (Pubitemid 17092838)
3. Staal GE, Rijksen G. The role of red cell aging in the diagnosis of glycolytic enzyme defects. Adv Exp Med Biol 1991; 307:239-249.
4. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 1997; 29:315-330. (Pubitemid 27498411)
5. Steinberg P, Klingelhoffer A, Schafer A, Wust G, Weisse G, Oesch F, Eigenbrodt E. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch 1999; 434:213-220. (Pubitemid 29186805)
6. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 1992; 3: 91-115.
7. Ibsen KH, Orlando RA, Garratt KN, Hernandez AM, Giorlando S, Nungaray G. Expression of multimolecular forms of pyruvate kinase in normal, benign, and malignant human breast tissue. Cancer Res 1982; 42:888-892.
8. Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 2000; 20:5151-5154. (Pubitemid 32319099)
9. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastrointestinal cancer. Anticancer Res 2000; 20:4965-4968. (Pubitemid 32319060)
10. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 2000; 20:4961-4964. (Pubitemid 32319059)
11. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003; 23:5089-5093. (Pubitemid 38182129)
12. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91:980-984. (Pubitemid 39273794)
13. Boren J, Lee WN, Bassilian S, Centelles JJ, Lim S, Ahmed S, et al. The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 2003; 278:28395-28402. (Pubitemid 36935740)
14. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23:851-853. (Pubitemid 36750884)
15. Zhang B, Chen JY, Chen DD, Wang GB, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004; 10:1643-1646. (Pubitemid 38786947)
16. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2- pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49:1149-1155. (Pubitemid 39178081)
17. Goldstein SA, Elwyn DH. The effects of injury and sepsis on fuel utilization. Annu Rev Nutr 1989; 9:445-473.
18. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig KH. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol 2005; 40:1493-1494. (Pubitemid 43028212)
19. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994; 69:409-415.
20. Johnson MW, Maestranzi S, Dewar DH, Forbes A, Bjarnason I, Sherwood R, et al. Validation of the new 'PhiCal' faecal Calprotectin test as a diagnostic tool for pouchitis. Gut 2006; 56 (Suppl II):A112.
21. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993; 30 (Pt 6):521-539.
22. Johnson MW, Maestranzi S, Dewar DH, Forbes A, Ciclitira PJ, Nicholls RJ. Faecal M2-pyruvate kinase: a novel non-invasive marker of ileal pouch inflammation. Gut 2006; 55 (Suppl 5):A116-A117.
23. Thomas P, Rihani H, Roseth A, Sigthorsson G, Price A, Nicholls RJ, Bjarnason I. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum 2000; 43:214-220. (Pubitemid 30115103)
24. Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994; 27:259-264. (Pubitemid 24300418)
25. Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126:1280-1286. (Pubitemid 38552792)
26. Johnson MW, Dewar DH, Ciclitira P, Forbes A, Nicholls RJ, Bjarnason I. Use of fecal lactoferrin to diagnose irritable pouch syndrome: a word of caution. Gastroenterology 2004; 127:1647-1648.
27. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27:793-798.
28. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47:506-513.
29. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123:450-460. (Pubitemid 34827189)
30. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58:176-180. (Pubitemid 27163169)
31. Jo K, Rutten B, Bunn RC, Bredt DS. Actinin-associated LIM protein-deficient mice maintain normal development and structure of skeletal muscle. Mol Cell Biol 2001; 21:1682-1687. (Pubitemid 32156388)
32. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15-22. (Pubitemid 30452574)
33. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54:364-368. (Pubitemid 40299092)
34. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39:1017-1020. (Pubitemid 39388470)
35. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19:2583-2590.
36. Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res 1999; 19:2753-2757. (Pubitemid 29392453)
37. Johnson MW, Man R, Dewar DH, Forbes A, Ciclitira P, Nicholls JR. Does pouchitis occur in familial adenomatous polyposis patients? Gut 2005; 54 (Suppl VII):A237 [abstract].
38. Gutteridge JM, Paterson SK, Segal AW, Halliwell B. Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J 1981; 199:259-261. (Pubitemid 12198624)
39. Alexander DP, Becker JM. Cefoxitin disposition in colorectal surgery. Implications for the effective use of prophylactic antibiotics. Ann Surg 1988; 208:162-168.
40. Das P, Johnson MW, Tekkis PP, Nicholls RJ. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2007; 9:15-27. (Pubitemid 44869672)